Haemonetics Corp. (MASS) surges on CSL Plasma partnership
The announcement that CSL Limited will roll out Haemonetics’ next‑generation plasmapheresis platform across its United States plasma collection centers has pushed the company’s shares to a new 52‑week high. The deal, which will be completed by the end of 2027, has prompted a sharp reassessment of Haemonetics’ revenue prospects by analysts and investors alike.
Market reaction
Within hours of the announcement, Haemonetics’ stock jumped 17 % to close at $119.56, marking the highest one‑day gain since the share hit $116.97 in April 2021. The move has driven the current price 43 % higher than its 2026‑year‑to‑date performance, positioning it among the strongest annual performers in the Health Care Equipment & Supplies sector this year.
The surge is reflected across the market: the Dow Jones Market Data reports the upward pressure on the stock, while broader market futures slipped on Thursday as rising bond yields and renewed inflation worries dampened the AI‑driven rally. Analysts have noted that the Haemonetics‑CSL partnership offers a tangible expansion of the company’s product footprint, potentially unlocking higher recurring revenue streams.
Analyst upgrades
BTIG, a leading research house, has lifted its price target from the mid‑$100 range to $130 following the announcement, citing the strategic importance of the CSL deal. This upgrade aligns with a broader consensus that Haemonetics’ automated blood processing systems will see increased adoption across surgical and plasma collection settings. The company’s current P/E ratio of 50.08 is viewed as a reflection of market optimism rather than overvaluation, given the expected earnings lift from the new partnership.
Strategic implications
The CSL collaboration represents a significant milestone in Haemonetics’ growth trajectory. By replacing CSL’s existing Terumo BCT Rika system, Haemonetics gains a foothold in a network that processes a substantial volume of plasma collection activity in the United States. The transition is expected to improve efficiency and reduce operational costs for CSL, thereby creating a recurring revenue stream for Haemonetics through service agreements, consumables, and support.
This development dovetails with Haemonetics’ broader strategy to expand its global reach. The company, headquartered in Boston, has historically focused on automated blood processing systems for surgical salvage and component collections. The new partnership signals a diversification into plasma collection, a market segment that has seen steady growth as demand for plasma‑derived therapeutics rises.
Outlook
With a market cap of approximately $4.7 billion and a close price of $101.71 as of 2026‑10‑06, Haemonetics is now positioned to capitalize on the projected expansion of CSL’s U.S. network. The company’s valuation remains high, but the 2027 rollout of the new plasmapheresis platform is expected to justify the premium. Investors should monitor the rollout progress and the resulting incremental revenue impact, which could justify further upgrades to the target price.
In sum, Haemonetics’ partnership with CSL marks a pivotal expansion of its product portfolio and presents a clear pathway to enhanced earnings. The market’s enthusiastic response underscores confidence in the company’s ability to execute this strategic initiative and deliver sustained value to shareholders.
